Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens

By                    

Oncology Letters, Vol. 2, Iss. 2, 2011-01 ,pp. : 247-251

Spandidos Publications

Access to resources Recommend Favorite

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer

By Takahari Daisuke   Shimada Yasuhiro   Takeshita Shigeyuki   Nishitani Hitoshi   Takashima Atsuo   Okita Natsuko   Hirashima Yoshinori   Kato Ken   Hamaguchi Tetsuya   Yamada Yasuhide   Shirao Kuniaki  

Gastric Cancer, Vol. 13, Iss. 3, 2010-08 ,pp. : 186-190

Springer Publishing Company

Access to resources Recommend Favorite

Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study

By Seto Takashi   Takezako Yoriko   Nakamura Hiroko   Takeda Kayo   Inoue Fumiko   Semba Hiroshi   Eguchi Kenji  

International Journal of Clinical Oncology, Vol. 9, Iss. 5, 2004-10 ,pp. : 378-382

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer

By Barone Carlo   Basso Michele   Schinzari Giovanni   Pozzo Carmelo   Trigila Nunziatina   D'Argento Ettore   Quirino Michela   Astone Antonio   Cassano Alessandra  

Gastric Cancer, Vol. 10, Iss. 2, 2007-06 ,pp. : 104-111

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer

By Alonso V.   Escudero P.   Zorrilla M.   Isla M.D.   Herrero A.   Mayordomo J.I.   Martinez-Trufero J.   Saenz A.   Tres A.   Anton A.  

European Journal of Cancer, Vol. 37, Iss. 18, 2001-12 ,pp. : 2385-2391

Elsevier

Access to resources Recommend Favorite